Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
Women with a history of the malignancy also survive longer than men after receiving a liver transplant.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
Sci-B-Vac may offer more protection for older people and those with a weaker immune system.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
Efforts to control viral hepatitis are falling behind, in part because of the growing opioid epidemic and homelessness crisis.
The change targets LGBT people and those with chronic conditions. Here’s how patient groups and Lambda Legal respond.
Help find the “missing millions” who don’t know they’re living with viral hepatitis.
Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Four things you should know to be #HepAware.
The drug is still associated with a lower liver cancer rate than Baraclude.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.